Cryoport, Inc. Files Q3 2024 10-Q

TL;DR

Cryoport's Q3 2024 10-Q is in. Check financials.

AI Summary

Cryoport, Inc. filed its 10-Q for the period ending September 30, 2024. The company, operating in pharmaceutical preparations, reported financial results for the third quarter of 2024. Key financial data and operational updates are detailed within the filing.

Why It Matters

This filing provides investors and stakeholders with the latest financial performance and operational details for Cryoport, Inc. during the third quarter of 2024.

Risk Assessment

Risk Level: medium — The filing is a standard quarterly report, but the company operates in the pharmaceutical sector which can be subject to regulatory and market risks.

Key Numbers

• Q3 2024 — Reporting Period (The company's financial performance for the third quarter of 2024 is detailed.)

Key Players & Entities

• Cryoport, Inc. (company) — Filer of the 10-Q
• 20240930 (date) — End of the reporting period
• 20241107 (date) — Filing date
• PHARMACEUTICAL PREPARATIONS [2834] (industry) — Company's Standard Industrial Classification

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value CYRX The Nasdaq Stock Mar

Filing Documents

• cyrx-20240930x10q.htm (10-Q) — 2670KB
• cyrx-20240930xex31d1.htm (EX-31.1) — 14KB
• cyrx-20240930xex31d2.htm (EX-31.2) — 13KB
• cyrx-20240930xex32d1.htm (EX-32.1) — 17KB
• cyrx-20240930x10q004.jpg (GRAPHIC) — 8KB
• 0001558370-24-014896.txt ( ) — 12317KB
• cyrx-20240930.xsd (EX-101.SCH) — 74KB
• cyrx-20240930_cal.xml (EX-101.CAL) — 99KB
• cyrx-20240930_def.xml (EX-101.DEF) — 307KB
• cyrx-20240930_lab.xml (EX-101.LAB) — 653KB
• cyrx-20240930_pre.xml (EX-101.PRE) — 524KB
• cyrx-20240930x10q_htm.xml (XML) — 2568KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

ITEM 1. Financial Statements Condensed Consolidated Balance Sheets at September 30, 2024 (Unaudited) and December 31, 2023 3 Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 4 Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 5 Unaudited Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2024 and 2023 6 Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 7 Notes to Condensed Consolidated Financial Statements (Unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 27

Quantitative and Qualitative Disclosures About Market Risk

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 37

Controls and Procedures

ITEM 4. Controls and Procedures 37

OTHER INFORMATION

PART II. OTHER INFORMATION 38

Legal Proceedings

ITEM 1. Legal Proceedings 38

Risk Factors

ITEM 1A. Risk Factors 38

Unregistered Sales of Equity Securities and Use of Proceeds

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 38

Defaults Upon Senior Securities

ITEM 3. Defaults Upon Senior Securities 38

Mine Safety Disclosures

ITEM 4. Mine Safety Disclosures 38

Other Information

ITEM 5. Other Information 38

Exhibits

ITEM 6. Exhibits 40

SIGNATURES

SIGNATURES 41 Table of Contents Cryoport, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except share data) September 30, December 31, 2024 2023 (unaudited) ASSETS Current Assets: Cash and cash equivalents $ 44,665 $ 46,346 Short-term investments 228,001 410,409 Accounts receivable, net 43,461 42,074 Inventories 23,552 26,206 Prepaid expenses and other current assets 10,658 10,077 Total current assets 350,337 535,112 Property and equipment, net 88,281 84,858 Operating lease right-of-use assets 30,113 32,653 Intangible assets, net 175,815 194,382 Goodwill 54,057 108,403 Deposits 1,493 1,680 Deferred tax assets 1,669 656 Total assets $ 701,765 $ 957,744 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable and other accrued expenses $ 25,194 $ 26,995 Accrued compensation and related expenses 11,275 11,409 Deferred revenue 1,091 1,308 Current portion of operating lease liabilities 5,834 5,371 Current portion of finance lease liabilities 470 286 Current portion of convertible senior notes, net of discount of $ 0.1 million 14,271 — Current portion of notes payable 153 149 Current portion of contingent consideration 3,151 92 Total current liabilities 61,439 45,610 Convertible senior notes, net of discount of $ 2.6 million and $ 7.0 million, respectively 183,628 378,553 Notes payable 1,238 1,335 Operating lease liabilities, net of current portion 26,466 29,355 Finance lease liabilities, net of current portion 1,306 954 Deferred tax liabilities 3,526 2,816 Other long-term liabilities 569 601 Contingent consideration, net of current portion 5,021 9,497 Total liabilities 283,193 468,721 Commitments and contingencies Stockholders' Equity: Preferred stock, $ 0.001 par value; 2,500,000 shares authorized: Class A convertible preferred stock - $ 0.001

View Full Filing

View this 10-Q filing on SEC EDGAR